Key Points
- CFO Keith Goldan sold 2,082 shares on Feb. 6 at an average price of $20.62 for $42,930.84, trimming his stake by 1.43% to 143,839 shares (≈$2.97M); the sale was disclosed in an SEC filing.
- Syndax (NASDAQ:SNDX) trades near $21 with a market cap of $1.83B, a negative P/E (-5.82), 50‑/200‑day moving averages of $20.67/$16.97, and a one‑year range of $8.58–$22.73.
- Wall Street shows a consensus "Moderate Buy" with an average target of $37.20 and price targets as high as $56, while institutional investors like AQR materially increased their positions (AQR up 478.8% to 377,444 shares).
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CFO Keith Goldan sold 2,082 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $20.62, for a total value of $42,930.84. Following the completion of the sale, the chief financial officer directly owned 143,839 shares of the company's stock, valued at approximately $2,965,960.18. The trade was a 1.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Syndax Pharmaceuticals Stock Performance
NASDAQ SNDX opened at $21.01 on Friday. The firm has a market capitalization of $1.83 billion, a P/E ratio of -5.82 and a beta of 0.46. The company has a current ratio of 4.64, a quick ratio of 4.42 and a debt-to-equity ratio of 2.78. The firm's fifty day moving average price is $20.67 and its two-hundred day moving average price is $16.97. Syndax Pharmaceuticals, Inc. has a 1 year low of $8.58 and a 1 year high of $22.73.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the company. BTIG Research reissued a "buy" rating and set a $56.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Syndax Pharmaceuticals in a research note on Monday, December 29th. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Syndax Pharmaceuticals in a report on Monday, October 27th. JPMorgan Chase & Co. cut their price target on Syndax Pharmaceuticals from $40.00 to $33.00 and set an "overweight" rating for the company in a report on Wednesday, November 12th. Finally, Barclays upped their price objective on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an "overweight" rating in a report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Syndax Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $37.20.
Get Our Latest Analysis on Syndax Pharmaceuticals
Institutional Investors Weigh In On Syndax Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC grew its stake in shares of Syndax Pharmaceuticals by 478.8% in the first quarter. AQR Capital Management LLC now owns 377,444 shares of the company's stock valued at $4,637,000 after acquiring an additional 312,231 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Syndax Pharmaceuticals by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,842 shares of the company's stock worth $705,000 after purchasing an additional 3,094 shares in the last quarter. Caxton Associates LLP acquired a new position in shares of Syndax Pharmaceuticals during the 1st quarter worth approximately $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Syndax Pharmaceuticals by 18.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 200,696 shares of the company's stock worth $2,466,000 after purchasing an additional 30,596 shares during the period. Finally, Aberdeen Group plc raised its position in shares of Syndax Pharmaceuticals by 129.1% in the second quarter. Aberdeen Group plc now owns 303,426 shares of the company's stock valued at $2,842,000 after buying an additional 170,993 shares in the last quarter.
About Syndax Pharmaceuticals
(
Get Free Report)
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax's research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.
The company's lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
